Clexio is a clinical-stage company designing novel drugs based on validated Mechanisms of Action in NeuroPsychiatry.
We are developing innovative therapies to address patients’ unmet needs in Major Depressive Disorder and Epilepsy.
Our lead drug candidate (CLE-100) is currently being tested in Phase 2 multicenter studies in the United States.
Our second candidate (CLE-043) is currently in preclinical stage, with lead compound identified.
